Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207951> ?p ?o ?g. }
- W4387207951 endingPage "S83" @default.
- W4387207951 startingPage "S82" @default.
- W4387207951 abstract "Testosterone (T) kinetics and its relationship with clinical outcomes has not been studied in trials using salvage radiotherapy and androgen deprivation therapy (ADT). We performed a secondary analysis of the NRG Oncology/RTOG 0534 SPPORT trial, which compared prostate bed radiotherapy (PBRT) (arm 1), PBRT + short-term androgen deprivation therapy (ADT) (arm 2), or PBRT + pelvic lymph node radiotherapy (PLNRT) + short-term ADT (arm 3). We assessed longitudinal serum T levels and the impact of testosterone recovery (TR) on clinical outcomes.ADT was given for 4-6 months in arms 2 and 3, starting 2 months prior to radiotherapy. The trial excluded patients with baseline T < 40% of the lower limit of normal. TR was defined in 3 ways: 1) return to non-castrate level (>50 ng/dL), 2) return to normal level (>300 ng/dL), and 3) return to baseline level. Time to TR was estimated using cumulative incidence and death without an event considered a competing risk. Unadjusted and adjusted hazard ratios and 95% confidence intervals (CIs) were calculated using Cox proportional hazards model. Freedom from progression (FFP) was defined as biochemical failure according to the Phoenix definition (PSA ≥2 ng/mL over the nadir PSA), clinical failure (local, regional, or distant), or death from any cause.A total of 1699 patients with T at baseline and at least 1 follow-up assessment were included. The median age was 64 years (IQR 59 - 69), 12.8% were black, 14.9% had diabetes, and 54.1% were former or current smokers. Median baseline T in arms 1, 2 and 3 was 320 ng/dL (IQR 239 - 424), 319 ng/dL (IQR 237 - 438) and 330 ng/dL (IQR 252 - 446), respectively. At 6 months, median T in arms 1, 2 and 3 was 290 ng/dL (IQR 210 - 390), 190.4 ng/dL (IQR 66 - 296) and 191 ng/dL (IQR 40.5 - 313). At 2 years, in arms 2 and 3, TR to non-castrate, normal and baseline levels were 95%, 55% and 23%, respectively. At 5 years, in arms 2 and 3, TR to non-castrate, normal and baseline levels were 98%, 73% and 42%, respectively. FFP was superior in arms 2 and 3 vs. arm 1 in patients with TR by all three definitions. In patients with recovered T to normal levels by 2 years (n = 904), the 5-year FFP rates were 71.8% (95% CI 66.9-76.6) in arm 1, 77.2% (72.1-82.2) in arm 2, and 86.3% (82.3-90.3) in arm 3 (arm 2 vs arm 1: HR 0.74, 95% CI 0.56-0.98, p = 0.034; arm 3 vs arm 1: HR 0.54, 95% CI 0.40-0.72, p<.0001).This work represents the largest study of T kinetics in patients treated with salvage radiation and ADT. Approximately half of patients did not normalize their T levels by 2 years. Our data validate an incremental and meaningful FFP benefit of adding short-term ADT and PLNRT to PBRT independent of T recovery." @default.
- W4387207951 created "2023-09-30" @default.
- W4387207951 creator A5008317954 @default.
- W4387207951 creator A5011708499 @default.
- W4387207951 creator A5017794411 @default.
- W4387207951 creator A5020006331 @default.
- W4387207951 creator A5023914087 @default.
- W4387207951 creator A5032441898 @default.
- W4387207951 creator A5033818119 @default.
- W4387207951 creator A5036433314 @default.
- W4387207951 creator A5038819739 @default.
- W4387207951 creator A5041009458 @default.
- W4387207951 creator A5044903935 @default.
- W4387207951 creator A5061685596 @default.
- W4387207951 creator A5062862337 @default.
- W4387207951 creator A5063389942 @default.
- W4387207951 creator A5066865022 @default.
- W4387207951 creator A5070623757 @default.
- W4387207951 creator A5073614518 @default.
- W4387207951 creator A5082555226 @default.
- W4387207951 creator A5089674017 @default.
- W4387207951 creator A5090936242 @default.
- W4387207951 date "2023-10-01" @default.
- W4387207951 modified "2023-10-17" @default.
- W4387207951 title "Impact of Testosterone Recovery on Clinical Outcomes of Patients Treated with Salvage Radiotherapy and Androgen Suppression: A Secondary Analysis of the NRG/RTOG 0534 Sport Phase 3 Trial" @default.
- W4387207951 doi "https://doi.org/10.1016/j.ijrobp.2023.06.403" @default.
- W4387207951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784585" @default.
- W4387207951 hasPublicationYear "2023" @default.
- W4387207951 type Work @default.
- W4387207951 citedByCount "0" @default.
- W4387207951 crossrefType "journal-article" @default.
- W4387207951 hasAuthorship W4387207951A5008317954 @default.
- W4387207951 hasAuthorship W4387207951A5011708499 @default.
- W4387207951 hasAuthorship W4387207951A5017794411 @default.
- W4387207951 hasAuthorship W4387207951A5020006331 @default.
- W4387207951 hasAuthorship W4387207951A5023914087 @default.
- W4387207951 hasAuthorship W4387207951A5032441898 @default.
- W4387207951 hasAuthorship W4387207951A5033818119 @default.
- W4387207951 hasAuthorship W4387207951A5036433314 @default.
- W4387207951 hasAuthorship W4387207951A5038819739 @default.
- W4387207951 hasAuthorship W4387207951A5041009458 @default.
- W4387207951 hasAuthorship W4387207951A5044903935 @default.
- W4387207951 hasAuthorship W4387207951A5061685596 @default.
- W4387207951 hasAuthorship W4387207951A5062862337 @default.
- W4387207951 hasAuthorship W4387207951A5063389942 @default.
- W4387207951 hasAuthorship W4387207951A5066865022 @default.
- W4387207951 hasAuthorship W4387207951A5070623757 @default.
- W4387207951 hasAuthorship W4387207951A5073614518 @default.
- W4387207951 hasAuthorship W4387207951A5082555226 @default.
- W4387207951 hasAuthorship W4387207951A5089674017 @default.
- W4387207951 hasAuthorship W4387207951A5090936242 @default.
- W4387207951 hasConcept C121608353 @default.
- W4387207951 hasConcept C126322002 @default.
- W4387207951 hasConcept C126894567 @default.
- W4387207951 hasConcept C143998085 @default.
- W4387207951 hasConcept C203092338 @default.
- W4387207951 hasConcept C207103383 @default.
- W4387207951 hasConcept C2777899217 @default.
- W4387207951 hasConcept C2778559712 @default.
- W4387207951 hasConcept C2779279991 @default.
- W4387207951 hasConcept C2780192828 @default.
- W4387207951 hasConcept C44249647 @default.
- W4387207951 hasConcept C50382708 @default.
- W4387207951 hasConcept C509974204 @default.
- W4387207951 hasConcept C535046627 @default.
- W4387207951 hasConcept C71924100 @default.
- W4387207951 hasConcept C72563966 @default.
- W4387207951 hasConcept C88879693 @default.
- W4387207951 hasConceptScore W4387207951C121608353 @default.
- W4387207951 hasConceptScore W4387207951C126322002 @default.
- W4387207951 hasConceptScore W4387207951C126894567 @default.
- W4387207951 hasConceptScore W4387207951C143998085 @default.
- W4387207951 hasConceptScore W4387207951C203092338 @default.
- W4387207951 hasConceptScore W4387207951C207103383 @default.
- W4387207951 hasConceptScore W4387207951C2777899217 @default.
- W4387207951 hasConceptScore W4387207951C2778559712 @default.
- W4387207951 hasConceptScore W4387207951C2779279991 @default.
- W4387207951 hasConceptScore W4387207951C2780192828 @default.
- W4387207951 hasConceptScore W4387207951C44249647 @default.
- W4387207951 hasConceptScore W4387207951C50382708 @default.
- W4387207951 hasConceptScore W4387207951C509974204 @default.
- W4387207951 hasConceptScore W4387207951C535046627 @default.
- W4387207951 hasConceptScore W4387207951C71924100 @default.
- W4387207951 hasConceptScore W4387207951C72563966 @default.
- W4387207951 hasConceptScore W4387207951C88879693 @default.
- W4387207951 hasIssue "2" @default.
- W4387207951 hasLocation W43872079511 @default.
- W4387207951 hasLocation W43872079512 @default.
- W4387207951 hasOpenAccess W4387207951 @default.
- W4387207951 hasPrimaryLocation W43872079511 @default.
- W4387207951 hasRelatedWork W2012724875 @default.
- W4387207951 hasRelatedWork W2042684539 @default.
- W4387207951 hasRelatedWork W2318819988 @default.
- W4387207951 hasRelatedWork W2761687716 @default.
- W4387207951 hasRelatedWork W2793295628 @default.
- W4387207951 hasRelatedWork W2802073086 @default.
- W4387207951 hasRelatedWork W3021633275 @default.
- W4387207951 hasRelatedWork W4220991042 @default.